Junshi Joins China mRNA Mania Through Immorna JV
Latest Partner For In-Demand Venture
Executive Summary
After immuno-oncology, mRNA is fast becoming a hot area in China as a flurry of biotechs from I-Mab to Kangtai partner with a little-known developer.
You may also be interested in...
Chinese Biotechs' Foray Into mRNA Enters New Chapter With $100m Everest Deal
Everest Medicines’ deal with Canadian biotech Providence Therapeutics contains a full transfer of technology which may be appealing to Chinese regulators.
Asia Deal Watch: GC Pharma Looks To Build On Enzyme Replacement Therapy Success
South Korean firm teams with Speragen to develop enzyme-replacement therapy for the genetic disorder and with Mirum for maralixibat. Plus deals involving Takeda/PeptiDream, Hanmi/LegoChem, Sun/Cassiopea, LegoChem/Cellectar, ChubLab/CJ CheilJedang Corp., Alebund/Chugai, Kintor/Fosun, Astellas/ExCellThera and I-Mab/neoX/Immorna.
China Biotech IPO Drought Lingers But HK Sees First Of 2024
Biotech IPOs on the Chinese mainland have dried up since June 2023 due to regulatory tightening, but Hong Kong is still open to listings of pre-revenue ventures and has seen its first offering of this year.